Cancer cells with deleterious mutations in BRCA1 or BRCA2 have defective HRR and the unrepaired DNA after treatment with PARPi will eventually lead to cancer cell death, a phenomenon called synthetic lethality. This evidence concerns the gene BRCA2 and cancer.